278 related articles for article (PubMed ID: 24566695)
61. Access to information supporting availability of medicines for patients suffering from rare diseases looking for possible treatments: the EuOrphan Service.
Stakisaitis D; Spokiene I; Juskevicius J; Valuckas KP; Baiardi P
Medicina (Kaunas); 2007; 43(6):441-6. PubMed ID: 17637514
[TBL] [Abstract][Full Text] [Related]
62. The emerging mental health strategy of the European Union: a multi-level work-in-progress.
Kelly BD
Health Policy; 2008 Jan; 85(1):60-70. PubMed ID: 17643547
[TBL] [Abstract][Full Text] [Related]
63. Silver paper: the future of health promotion and preventive actions, basic research, and clinical aspects of age-related disease--a report of the European Summit on Age-Related Disease.
Cruz-Jentoft AJ; Franco A; Sommer P; Baeyens JP; Jankowska E; Maggi A; Ponikowski P; Rys A; Szczerbinska K; Michel JP; Milewicz A
Aging Clin Exp Res; 2009 Dec; 21(6):376-85. PubMed ID: 20154507
[TBL] [Abstract][Full Text] [Related]
64. eHealth in Europe: from Vision to Reality.
Iakovidis I; Purcarea O
Stud Health Technol Inform; 2008; 134():163-8. PubMed ID: 18376043
[TBL] [Abstract][Full Text] [Related]
65. Health law and policy in the European Union.
Greer SL; Hervey TK; Mackenbach JP; McKee M
Lancet; 2013 Mar; 381(9872):1135-44. PubMed ID: 23541054
[TBL] [Abstract][Full Text] [Related]
66. Emerging infectious diseases not covered by routine vaccination in Europe in 2010-2015--the review of WHO and ECDC notifications for the National IHR Focal Point in Poland.
Henszel Ł; Janiec J; Izdebski R; Radziszewski F; Polański P
Przegl Epidemiol; 2015; 69(4):679-86, 829-36. PubMed ID: 27139344
[TBL] [Abstract][Full Text] [Related]
67. [Transnational solidarity? Cross-border heath-care in the European Union].
Schmucker R
Gesundheitswesen; 2010 Mar; 72(3):150-3. PubMed ID: 20191439
[TBL] [Abstract][Full Text] [Related]
68. Public health research on rare diseases.
Alonso V; Villaverde-Hueso A; Hens M; Morales-Piga A; Abaitua I; Posada de la Paz M
Georgian Med News; 2011 Apr; (193):11-6. PubMed ID: 21617266
[TBL] [Abstract][Full Text] [Related]
69. [Orphanet and its consortium: where to find expert-validated information on rare diseases].
Maiella S; Rath A; Angin C; Mousson F; Kremp O
Rev Neurol (Paris); 2013 Feb; 169 Suppl 1():S3-8. PubMed ID: 23452769
[TBL] [Abstract][Full Text] [Related]
70. [National Cancer Registry. Significance of a reliable database in the implementation of the required structural changes of cancer care in Hungary].
Kásler M; Ottó S; Sólyom O
Orv Hetil; 2014 Sep; 155(36):1415-20. PubMed ID: 25176515
[TBL] [Abstract][Full Text] [Related]
71. Centres of Expertise and European Reference Networks: key issues in the field of rare diseases. The EUCERD Recommendations.
Taruscio D; Gentile AE; Evangelista T; Frazzica RG; Bushby K; Montserrat AM
Blood Transfus; 2014 Apr; 12 Suppl 3(Suppl 3):s621-5. PubMed ID: 24922304
[TBL] [Abstract][Full Text] [Related]
72. A framework to start the debate on neonatal screening policies in the EU: an Expert Opinion Document.
Cornel MC; Rigter T; Weinreich SS; Burgard P; Hoffmann GF; Lindner M; Gerard Loeber J; Rupp K; Taruscio D; Vittozzi L
Eur J Hum Genet; 2014 Jan; 22(1):12-7. PubMed ID: 23652378
[TBL] [Abstract][Full Text] [Related]
73. A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation.
Pinxten W; Denier Y; Dooms M; Cassiman JJ; Dierickx K
J Med Ethics; 2012 Mar; 38(3):148-53. PubMed ID: 21947805
[TBL] [Abstract][Full Text] [Related]
74. Public health research systems in the European union.
Conceição C; McCarthy M
Health Res Policy Syst; 2011 Oct; 9():38. PubMed ID: 21970897
[TBL] [Abstract][Full Text] [Related]
75. Interoperability Architecture for a Paediatric Oncology European Reference Network.
Nitzlnader M; Canete Nieto A; Ribelles AJ; Brunmair B; Ladenstein R; Schreier G
Stud Health Technol Inform; 2016; 223():39-45. PubMed ID: 27139383
[TBL] [Abstract][Full Text] [Related]
76. Shared decision making in Spain: current state and future perspectives.
Perestelo-Perez L; Rivero-Santana A; Perez-Ramos J; Gonzalez-Lorenzo M; Roman JG; Serrano-Aguilar P
Z Evid Fortbild Qual Gesundhwes; 2011; 105(4):289-95. PubMed ID: 21620323
[TBL] [Abstract][Full Text] [Related]
77. Peer, professional, and public: an analysis of the drugs policy advocacy community in Europe.
O'Gorman A; Quigley E; Zobel F; Moore K
Int J Drug Policy; 2014 Sep; 25(5):1001-8. PubMed ID: 24974366
[TBL] [Abstract][Full Text] [Related]
78. Rare disease policies to improve care for patients in Europe.
Rodwell C; Aymé S
Biochim Biophys Acta; 2015 Oct; 1852(10 Pt B):2329-35. PubMed ID: 25725454
[TBL] [Abstract][Full Text] [Related]
79. Population health targets in Europe.
McCarthy M
Lancet; 1999 Nov; 354(9191):1663-4. PubMed ID: 10568565
[TBL] [Abstract][Full Text] [Related]
80. [The European Alcohol Action Plan. The Alcohol, Drug and Tobacco Unit. Department of Lifestyles and Health, Regional Office for Europe. World Health Organization. Copenhagen, 1993].
Gil López E; Robledo de Dios T; Rubio Colavida J; García Gómez M; Vargas Marcos F
Rev Esp Salud Publica; 1995; 69(5):361-83. PubMed ID: 8564857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
